| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy | 77 | 2021 | 981 | 3.760 |
Why?
|
| Pregnancy Complications | 17 | 2018 | 111 | 3.210 |
Why?
|
| Postpartum Hemorrhage | 13 | 2020 | 18 | 2.110 |
Why?
|
| Oxytocics | 6 | 2017 | 13 | 2.100 |
Why?
|
| Labor, Induced | 9 | 2018 | 17 | 2.070 |
Why?
|
| Cesarean Section | 17 | 2020 | 113 | 2.020 |
Why?
|
| Oxytocin | 7 | 2017 | 29 | 1.770 |
Why?
|
| Receptors, Oxytocin | 4 | 2017 | 8 | 1.740 |
Why?
|
| Delivery, Obstetric | 13 | 2020 | 58 | 1.590 |
Why?
|
| Pregnancy Outcome | 14 | 2018 | 91 | 1.550 |
Why?
|
| Female | 89 | 2021 | 20271 | 1.550 |
Why?
|
| Adult | 56 | 2021 | 9569 | 1.420 |
Why?
|
| Uterine Contraction | 4 | 2016 | 7 | 1.400 |
Why?
|
| Uterus | 4 | 2016 | 79 | 1.340 |
Why?
|
| Pre-Eclampsia | 6 | 2020 | 66 | 1.320 |
Why?
|
| Obstetric Labor Complications | 5 | 2017 | 17 | 1.310 |
Why?
|
| Humans | 87 | 2021 | 32814 | 1.140 |
Why?
|
| Chorioamnionitis | 5 | 2018 | 10 | 1.110 |
Why?
|
| Magnesium Sulfate | 2 | 2018 | 14 | 1.070 |
Why?
|
| G-Protein-Coupled Receptor Kinases | 2 | 2017 | 2 | 1.020 |
Why?
|
| Pregnancy Complications, Cardiovascular | 3 | 2018 | 25 | 1.010 |
Why?
|
| Cerebral Palsy | 2 | 2018 | 66 | 1.010 |
Why?
|
| Fibrinolytic Agents | 2 | 2017 | 69 | 0.990 |
Why?
|
| Labor, Obstetric | 5 | 2020 | 35 | 0.910 |
Why?
|
| Gestational Age | 13 | 2020 | 129 | 0.900 |
Why?
|
| Trial of Labor | 3 | 2020 | 19 | 0.900 |
Why?
|
| Adrenomedullin | 3 | 2014 | 3 | 0.880 |
Why?
|
| Premature Birth | 7 | 2021 | 72 | 0.860 |
Why?
|
| Young Adult | 21 | 2021 | 2734 | 0.790 |
Why?
|
| Logistic Models | 14 | 2018 | 783 | 0.790 |
Why?
|
| Fetal Membranes, Premature Rupture | 6 | 2019 | 13 | 0.780 |
Why?
|
| Trophoblasts | 2 | 2013 | 8 | 0.770 |
Why?
|
| Pyelonephritis | 4 | 2015 | 9 | 0.770 |
Why?
|
| Smoke | 2 | 2013 | 16 | 0.760 |
Why?
|
| Cervix Uteri | 3 | 2012 | 26 | 0.750 |
Why?
|
| Misoprostol | 2 | 2016 | 5 | 0.740 |
Why?
|
| Infant, Newborn | 11 | 2021 | 694 | 0.730 |
Why?
|
| Body Mass Index | 10 | 2018 | 908 | 0.730 |
Why?
|
| Ultrasonography, Prenatal | 3 | 2014 | 44 | 0.710 |
Why?
|
| Pregnancy Trimester, Third | 4 | 2020 | 18 | 0.700 |
Why?
|
| Diabetes, Gestational | 2 | 2014 | 27 | 0.690 |
Why?
|
| Patient Participation | 1 | 2020 | 87 | 0.610 |
Why?
|
| Seat Belts | 2 | 2015 | 17 | 0.570 |
Why?
|
| Abortion, Spontaneous | 2 | 2010 | 10 | 0.570 |
Why?
|
| Progesterone | 2 | 2015 | 69 | 0.570 |
Why?
|
| Stillbirth | 2 | 2016 | 13 | 0.560 |
Why?
|
| Obesity, Morbid | 5 | 2018 | 69 | 0.560 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2018 | 11 | 0.560 |
Why?
|
| Labor Presentation | 1 | 2018 | 1 | 0.560 |
Why?
|
| Retinopathy of Prematurity | 1 | 2018 | 9 | 0.550 |
Why?
|
| Magnesium | 1 | 2018 | 30 | 0.550 |
Why?
|
| Cytokines | 2 | 2016 | 247 | 0.550 |
Why?
|
| Fetal Blood | 1 | 2018 | 38 | 0.540 |
Why?
|
| Infant Mortality | 1 | 2018 | 26 | 0.540 |
Why?
|
| Retrospective Studies | 17 | 2020 | 3705 | 0.540 |
Why?
|
| Cell Movement | 3 | 2013 | 172 | 0.540 |
Why?
|
| Decidua | 2 | 2016 | 11 | 0.540 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2015 | 37 | 0.530 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2017 | 41 | 0.530 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2018 | 28 | 0.530 |
Why?
|
| Pregnancy Trimester, First | 2 | 2014 | 8 | 0.520 |
Why?
|
| Risk Factors | 17 | 2016 | 3976 | 0.520 |
Why?
|
| Neuroprotective Agents | 1 | 2017 | 27 | 0.520 |
Why?
|
| Tranexamic Acid | 1 | 2017 | 5 | 0.520 |
Why?
|
| Antifibrinolytic Agents | 1 | 2017 | 16 | 0.510 |
Why?
|
| Thrombin | 1 | 2016 | 16 | 0.510 |
Why?
|
| Blood Coagulation | 1 | 2017 | 18 | 0.510 |
Why?
|
| Heparin | 1 | 2016 | 70 | 0.500 |
Why?
|
| Pregnant Women | 1 | 2015 | 6 | 0.480 |
Why?
|
| Myometrium | 2 | 2013 | 9 | 0.480 |
Why?
|
| Continental Population Groups | 2 | 2016 | 236 | 0.470 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 148 | 0.470 |
Why?
|
| Uterine Inertia | 2 | 2016 | 2 | 0.460 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2015 | 26 | 0.460 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 32 | 0.460 |
Why?
|
| Health Status Disparities | 1 | 2016 | 134 | 0.460 |
Why?
|
| Vitamin D | 1 | 2016 | 189 | 0.460 |
Why?
|
| Hospitalization | 2 | 2015 | 488 | 0.450 |
Why?
|
| Pregnancy in Diabetics | 1 | 2014 | 6 | 0.450 |
Why?
|
| Thrombophilia | 1 | 2014 | 8 | 0.450 |
Why?
|
| Rheumatic Diseases | 1 | 2014 | 7 | 0.450 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 682 | 0.440 |
Why?
|
| Maternal Age | 1 | 2014 | 14 | 0.430 |
Why?
|
| Cystic Fibrosis | 1 | 2014 | 23 | 0.430 |
Why?
|
| Cerclage, Cervical | 2 | 2012 | 6 | 0.420 |
Why?
|
| Muscle Contraction | 3 | 2020 | 113 | 0.420 |
Why?
|
| Ethnic Groups | 1 | 2016 | 474 | 0.420 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 66 | 0.400 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 1066 | 0.400 |
Why?
|
| Inflammation | 1 | 2016 | 536 | 0.390 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 237 | 0.390 |
Why?
|
| Smoking | 2 | 2014 | 531 | 0.380 |
Why?
|
| Prevalence | 5 | 2018 | 1002 | 0.380 |
Why?
|
| United States | 8 | 2020 | 4109 | 0.380 |
Why?
|
| Obesity | 3 | 2017 | 1152 | 0.370 |
Why?
|
| Chorion | 5 | 2015 | 9 | 0.370 |
Why?
|
| Kidney Diseases | 1 | 2014 | 250 | 0.370 |
Why?
|
| Tobacco | 1 | 2012 | 58 | 0.350 |
Why?
|
| Uterine Hemorrhage | 1 | 2011 | 9 | 0.350 |
Why?
|
| Arrestins | 1 | 2010 | 3 | 0.340 |
Why?
|
| Labor Onset | 1 | 2010 | 1 | 0.340 |
Why?
|
| Blood Transfusion | 3 | 2020 | 76 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 622 | 0.340 |
Why?
|
| Signal Transduction | 2 | 2013 | 687 | 0.330 |
Why?
|
| Vaginal Fistula | 1 | 2010 | 2 | 0.330 |
Why?
|
| Fistula | 1 | 2010 | 11 | 0.330 |
Why?
|
| Hypertension | 2 | 2014 | 976 | 0.330 |
Why?
|
| Linear Models | 4 | 2014 | 445 | 0.310 |
Why?
|
| Case-Control Studies | 5 | 2017 | 877 | 0.310 |
Why?
|
| Prospective Studies | 5 | 2020 | 2329 | 0.300 |
Why?
|
| Adolescent | 9 | 2020 | 3640 | 0.290 |
Why?
|
| Time Factors | 6 | 2017 | 2183 | 0.290 |
Why?
|
| Hydatidiform Mole | 1 | 2008 | 4 | 0.280 |
Why?
|
| Uterine Rupture | 1 | 2008 | 18 | 0.280 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 29 | 0.280 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2008 | 17 | 0.280 |
Why?
|
| Postpartum Period | 3 | 2016 | 37 | 0.270 |
Why?
|
| Cohort Studies | 7 | 2020 | 1844 | 0.270 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 1140 | 0.260 |
Why?
|
| Birth Weight | 2 | 2018 | 49 | 0.250 |
Why?
|
| Alkalosis | 1 | 2006 | 2 | 0.240 |
Why?
|
| Pica | 1 | 2006 | 2 | 0.240 |
Why?
|
| Sodium Bicarbonate | 1 | 2006 | 6 | 0.240 |
Why?
|
| Rhabdomyolysis | 1 | 2006 | 6 | 0.240 |
Why?
|
| Hypokalemia | 1 | 2006 | 14 | 0.240 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 1 | 2005 | 1 | 0.240 |
Why?
|
| Abortion, Incomplete | 1 | 2005 | 1 | 0.240 |
Why?
|
| Cells, Cultured | 4 | 2018 | 820 | 0.240 |
Why?
|
| Extraembryonic Membranes | 3 | 2014 | 4 | 0.230 |
Why?
|
| Hydroxyprogesterones | 2 | 2015 | 4 | 0.230 |
Why?
|
| Blood Component Transfusion | 3 | 2016 | 10 | 0.230 |
Why?
|
| Prenatal Diagnosis | 3 | 2018 | 26 | 0.230 |
Why?
|
| Perineum | 2 | 2020 | 18 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 3 | 2018 | 789 | 0.230 |
Why?
|
| Odds Ratio | 3 | 2015 | 467 | 0.220 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2004 | 13 | 0.220 |
Why?
|
| Varicose Veins | 2 | 2018 | 6 | 0.220 |
Why?
|
| Ureteral Obstruction | 1 | 2004 | 28 | 0.220 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2015 | 31 | 0.220 |
Why?
|
| Progestins | 2 | 2015 | 22 | 0.220 |
Why?
|
| Suture Techniques | 1 | 2004 | 61 | 0.210 |
Why?
|
| Hysterectomy | 2 | 2020 | 49 | 0.210 |
Why?
|
| Prenatal Care | 3 | 2017 | 54 | 0.210 |
Why?
|
| Receptors, Progesterone | 2 | 2014 | 51 | 0.210 |
Why?
|
| Animals | 7 | 2020 | 7570 | 0.200 |
Why?
|
| RNA, Messenger | 3 | 2015 | 498 | 0.200 |
Why?
|
| Malignant Hyperthermia | 1 | 2003 | 4 | 0.200 |
Why?
|
| Cell Line | 3 | 2013 | 433 | 0.200 |
Why?
|
| Male | 9 | 2020 | 19650 | 0.200 |
Why?
|
| Muscular Diseases | 1 | 2003 | 23 | 0.200 |
Why?
|
| Gene Expression | 2 | 2016 | 334 | 0.190 |
Why?
|
| Respiratory Insufficiency | 1 | 2003 | 59 | 0.190 |
Why?
|
| Membrane Proteins | 2 | 2014 | 251 | 0.180 |
Why?
|
| Accidents, Traffic | 2 | 2015 | 197 | 0.180 |
Why?
|
| Models, Statistical | 2 | 2020 | 180 | 0.170 |
Why?
|
| Steroids | 1 | 2021 | 34 | 0.170 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 475 | 0.170 |
Why?
|
| Expert Systems | 1 | 2020 | 4 | 0.160 |
Why?
|
| Uterine Artery Embolization | 1 | 2020 | 3 | 0.160 |
Why?
|
| Birthing Centers | 1 | 2020 | 1 | 0.160 |
Why?
|
| Wounds and Injuries | 2 | 2013 | 245 | 0.160 |
Why?
|
| Computer Graphics | 1 | 2020 | 10 | 0.160 |
Why?
|
| Lacerations | 1 | 2020 | 9 | 0.160 |
Why?
|
| Amnion | 3 | 2015 | 37 | 0.160 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 63 | 0.160 |
Why?
|
| Operating Rooms | 1 | 2020 | 43 | 0.160 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 72 | 0.150 |
Why?
|
| Double-Blind Method | 2 | 2020 | 525 | 0.150 |
Why?
|
| Vaccination | 2 | 2017 | 146 | 0.150 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 247 | 0.150 |
Why?
|
| Tocolysis | 1 | 2019 | 1 | 0.150 |
Why?
|
| Tocolytic Agents | 1 | 2019 | 1 | 0.150 |
Why?
|
| Obstetric Labor, Premature | 1 | 2019 | 11 | 0.150 |
Why?
|
| Vaginal Birth after Cesarean | 1 | 2019 | 26 | 0.150 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2018 | 23 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2015 | 3441 | 0.150 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2018 | 3 | 0.150 |
Why?
|
| Genotype | 3 | 2017 | 731 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 133 | 0.150 |
Why?
|
| Mice, Knockout | 2 | 2020 | 453 | 0.150 |
Why?
|
| Respiration, Artificial | 2 | 2013 | 98 | 0.150 |
Why?
|
| African Americans | 2 | 2016 | 1424 | 0.140 |
Why?
|
| Fetal Weight | 2 | 2018 | 6 | 0.140 |
Why?
|
| Abdominal Wall | 1 | 2018 | 22 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2020 | 182 | 0.140 |
Why?
|
| Risk Assessment | 3 | 2020 | 1461 | 0.140 |
Why?
|
| Fetal Development | 1 | 2018 | 27 | 0.140 |
Why?
|
| Hispanic Americans | 2 | 2016 | 930 | 0.140 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 82 | 0.140 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 57 | 0.140 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2018 | 107 | 0.140 |
Why?
|
| Decision Making | 1 | 2020 | 202 | 0.140 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 5 | 0.140 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 24 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 252 | 0.140 |
Why?
|
| Rh-Hr Blood-Group System | 2 | 2008 | 5 | 0.140 |
Why?
|
| North Carolina | 6 | 2020 | 1546 | 0.140 |
Why?
|
| Anticonvulsants | 1 | 2018 | 65 | 0.130 |
Why?
|
| Forecasting | 1 | 2018 | 143 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 888 | 0.130 |
Why?
|
| Data Collection | 1 | 2017 | 185 | 0.130 |
Why?
|
| False Positive Reactions | 2 | 2008 | 26 | 0.130 |
Why?
|
| Thrombelastography | 1 | 2017 | 3 | 0.130 |
Why?
|
| Infant | 2 | 2018 | 1083 | 0.130 |
Why?
|
| Muscle, Smooth | 1 | 2017 | 69 | 0.130 |
Why?
|
| Calcium Channels | 1 | 2017 | 61 | 0.130 |
Why?
|
| Mice | 4 | 2020 | 2512 | 0.120 |
Why?
|
| Regression Analysis | 2 | 2021 | 288 | 0.120 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2015 | 3 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 65 | 0.120 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 524 | 0.120 |
Why?
|
| Ultrasonography | 2 | 2010 | 381 | 0.120 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2015 | 19 | 0.120 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 38 | 0.120 |
Why?
|
| Hydroxylation | 1 | 2015 | 5 | 0.120 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2015 | 4 | 0.120 |
Why?
|
| Microsomes | 1 | 2015 | 13 | 0.120 |
Why?
|
| Workload | 1 | 2015 | 40 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2016 | 191 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2015 | 71 | 0.110 |
Why?
|
| Isoenzymes | 1 | 2015 | 59 | 0.110 |
Why?
|
| Pregnancy, Animal | 1 | 2015 | 19 | 0.110 |
Why?
|
| Telemetry | 1 | 2015 | 29 | 0.110 |
Why?
|
| Placenta | 1 | 2016 | 75 | 0.110 |
Why?
|
| Pregnancy, Multiple | 1 | 2015 | 9 | 0.110 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2015 | 100 | 0.110 |
Why?
|
| Protein Precursors | 1 | 2014 | 19 | 0.110 |
Why?
|
| Disease Management | 1 | 2015 | 128 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 98 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 97 | 0.110 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 2 | 2015 | 2 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1572 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 532 | 0.110 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2013 | 3 | 0.110 |
Why?
|
| Professional Practice | 1 | 2014 | 24 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 213 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2015 | 205 | 0.110 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2013 | 8 | 0.100 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2013 | 2 | 0.100 |
Why?
|
| Fibrinolysis | 1 | 2013 | 7 | 0.100 |
Why?
|
| Autistic Disorder | 1 | 2013 | 8 | 0.100 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 24 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2014 | 116 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 292 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 131 | 0.100 |
Why?
|
| Anemia | 1 | 2013 | 57 | 0.100 |
Why?
|
| Hormone Antagonists | 1 | 2013 | 3 | 0.100 |
Why?
|
| Bacteria | 1 | 2014 | 55 | 0.100 |
Why?
|
| Diabetes Mellitus | 2 | 2014 | 422 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2014 | 486 | 0.100 |
Why?
|
| Uterine Cervical Incompetence | 1 | 2012 | 3 | 0.090 |
Why?
|
| European Continental Ancestry Group | 1 | 2016 | 1163 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 256 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2013 | 136 | 0.090 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 10 | 0.090 |
Why?
|
| Cervical Ripening | 1 | 2011 | 2 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 10 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2014 | 494 | 0.090 |
Why?
|
| Catheterization | 1 | 2011 | 57 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2015 | 324 | 0.090 |
Why?
|
| Age Factors | 1 | 2014 | 1197 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 118 | 0.090 |
Why?
|
| Cell Survival | 1 | 2012 | 281 | 0.090 |
Why?
|
| Middle Aged | 5 | 2020 | 12133 | 0.090 |
Why?
|
| Stimulation, Chemical | 1 | 2010 | 13 | 0.090 |
Why?
|
| Palpation | 1 | 2010 | 9 | 0.080 |
Why?
|
| Hematocrit | 1 | 2010 | 23 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2011 | 240 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2010 | 37 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2010 | 92 | 0.080 |
Why?
|
| Pregnancy, High-Risk | 1 | 2010 | 3 | 0.080 |
Why?
|
| Rh Isoimmunization | 2 | 2008 | 2 | 0.080 |
Why?
|
| Transfection | 1 | 2010 | 184 | 0.080 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 113 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2010 | 287 | 0.080 |
Why?
|
| Nicotine | 1 | 2012 | 177 | 0.080 |
Why?
|
| Abortion, Therapeutic | 1 | 2008 | 1 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 332 | 0.070 |
Why?
|
| Suction | 1 | 2008 | 10 | 0.070 |
Why?
|
| Pregnancy, Ectopic | 1 | 2008 | 7 | 0.070 |
Why?
|
| Intensive Care Units | 1 | 2009 | 115 | 0.070 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2008 | 3 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 1 | 2008 | 52 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2010 | 603 | 0.070 |
Why?
|
| Glucose Tolerance Test | 1 | 2008 | 125 | 0.070 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2007 | 2 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 2285 | 0.070 |
Why?
|
| Infant, Premature, Diseases | 2 | 2020 | 26 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2007 | 38 | 0.060 |
Why?
|
| Oligomenorrhea | 1 | 2006 | 1 | 0.060 |
Why?
|
| Anovulation | 1 | 2006 | 4 | 0.060 |
Why?
|
| Anal Canal | 1 | 2006 | 20 | 0.060 |
Why?
|
| Bariatric Surgery | 1 | 2006 | 25 | 0.060 |
Why?
|
| Dystocia | 1 | 2005 | 2 | 0.060 |
Why?
|
| Endometrium | 1 | 2005 | 42 | 0.060 |
Why?
|
| Birth Injuries | 1 | 2005 | 28 | 0.060 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2005 | 36 | 0.060 |
Why?
|
| Pregnancy, Prolonged | 1 | 2004 | 1 | 0.060 |
Why?
|
| Uterine Diseases | 1 | 2004 | 9 | 0.060 |
Why?
|
| Hemostatic Techniques | 1 | 2004 | 7 | 0.060 |
Why?
|
| Ultrasonography, Doppler | 1 | 2004 | 24 | 0.060 |
Why?
|
| Endometriosis | 1 | 2004 | 25 | 0.050 |
Why?
|
| Radiography | 1 | 2004 | 386 | 0.050 |
Why?
|
| Prognosis | 2 | 2018 | 1545 | 0.040 |
Why?
|
| Fetal Macrosomia | 2 | 2014 | 6 | 0.040 |
Why?
|
| Child | 2 | 2020 | 2478 | 0.040 |
Why?
|
| Perinatal Mortality | 1 | 2020 | 3 | 0.040 |
Why?
|
| Morbidity | 1 | 2021 | 101 | 0.040 |
Why?
|
| Fetal Distress | 1 | 2020 | 3 | 0.040 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2020 | 6 | 0.040 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2020 | 23 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 168 | 0.040 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2020 | 37 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 576 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2020 | 51 | 0.040 |
Why?
|
| Obstetrics | 1 | 2020 | 28 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 75 | 0.040 |
Why?
|
| Clenbuterol | 1 | 2018 | 2 | 0.040 |
Why?
|
| Phenotype | 1 | 2021 | 638 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2018 | 29 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2019 | 30 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 50 | 0.040 |
Why?
|
| Models, Econometric | 1 | 2018 | 9 | 0.040 |
Why?
|
| Polysomnography | 1 | 2018 | 40 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2018 | 46 | 0.040 |
Why?
|
| Growth Charts | 1 | 2018 | 4 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 69 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2018 | 157 | 0.030 |
Why?
|
| Reference Values | 1 | 2018 | 238 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 194 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 881 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 2016 | 13 | 0.030 |
Why?
|
| DNA | 2 | 2008 | 218 | 0.030 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2015 | 10 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 767 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 2015 | 11 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2015 | 15 | 0.030 |
Why?
|
| Pressure | 1 | 2015 | 51 | 0.030 |
Why?
|
| Urologic Neoplasms | 1 | 2015 | 14 | 0.030 |
Why?
|
| Neuromuscular Diseases | 1 | 2015 | 15 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 2015 | 26 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 41 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 16 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 80 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 130 | 0.030 |
Why?
|
| Pneumonia | 1 | 2015 | 64 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 258 | 0.030 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2014 | 1 | 0.030 |
Why?
|
| Hemostatics | 1 | 2014 | 11 | 0.030 |
Why?
|
| Expert Testimony | 1 | 2014 | 11 | 0.030 |
Why?
|
| Fetal Growth Retardation | 1 | 2014 | 34 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2014 | 18 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 1 | 2013 | 1 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 32 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2013 | 3 | 0.030 |
Why?
|
| Antithrombin III | 1 | 2013 | 4 | 0.030 |
Why?
|
| Hypothermia, Induced | 1 | 2013 | 16 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 42 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2013 | 17 | 0.030 |
Why?
|
| Developmental Disabilities | 1 | 2013 | 18 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2013 | 43 | 0.030 |
Why?
|
| Birth Certificates | 1 | 2013 | 4 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 84 | 0.030 |
Why?
|
| Parity | 1 | 2013 | 19 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2013 | 70 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 526 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2015 | 127 | 0.020 |
Why?
|
| Abruptio Placentae | 1 | 2013 | 7 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 133 | 0.020 |
Why?
|
| Fetal Death | 1 | 2013 | 11 | 0.020 |
Why?
|
| Air Bags | 1 | 2013 | 15 | 0.020 |
Why?
|
| Schools | 1 | 2013 | 67 | 0.020 |
Why?
|
| Motor Vehicles | 1 | 2013 | 25 | 0.020 |
Why?
|
| Medical Records | 1 | 2013 | 77 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 308 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 315 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2015 | 338 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 497 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 563 | 0.020 |
Why?
|
| Ampicillin | 1 | 2011 | 2 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 565 | 0.020 |
Why?
|
| Emergencies | 1 | 2012 | 45 | 0.020 |
Why?
|
| Azithromycin | 1 | 2011 | 16 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 676 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 156 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 315 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 520 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 412 | 0.020 |
Why?
|
| Mothers | 1 | 2011 | 91 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 1282 | 0.020 |
Why?
|
| New Jersey | 1 | 2009 | 9 | 0.020 |
Why?
|
| Apgar Score | 1 | 2009 | 8 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2009 | 33 | 0.020 |
Why?
|
| Oocyte Retrieval | 1 | 2008 | 1 | 0.020 |
Why?
|
| Ovulation Induction | 1 | 2008 | 3 | 0.020 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2008 | 4 | 0.020 |
Why?
|
| Fertilization in Vitro | 1 | 2008 | 14 | 0.020 |
Why?
|
| Live Birth | 1 | 2008 | 5 | 0.020 |
Why?
|
| Hemostasis, Surgical | 1 | 2008 | 13 | 0.020 |
Why?
|
| Embryo Transfer | 1 | 2008 | 6 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2008 | 19 | 0.020 |
Why?
|
| Balloon Occlusion | 1 | 2008 | 37 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1239 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 125 | 0.020 |
Why?
|
| Pregnancy Trimesters | 1 | 2006 | 3 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 43 | 0.020 |
Why?
|
| Recurrence | 1 | 2007 | 282 | 0.020 |
Why?
|
| Health Surveys | 1 | 2006 | 200 | 0.020 |
Why?
|
| Episiotomy | 1 | 2005 | 2 | 0.010 |
Why?
|
| Obstetrical Forceps | 1 | 2005 | 3 | 0.010 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2005 | 4 | 0.010 |
Why?
|
| Maryland | 1 | 2005 | 28 | 0.010 |
Why?
|
| Databases as Topic | 1 | 2005 | 21 | 0.010 |
Why?
|
| Weight Loss | 1 | 2006 | 457 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 1307 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 4034 | 0.010 |
Why?
|
| Aged | 1 | 2004 | 10544 | 0.010 |
Why?
|